GI Oncology Today: Multitarget Stool RNA Test Proves Sensitive for Colorectal Cancer, Advanced Adenomas

Erica Barnell, MD, PhD, of Washington University School of Medicine, and founder of Geneoscopy Inc, describes the multitarget stool RNA…


Closing the Gap: Why Healthcare Needs More Gender Diversity in Leadership

"Embrace your flaws: Everyone has flaws. I feel that I have been successful because I am able to recognize these flaws, understand where I need…


Geneoscopy receives Z-Code from Palmetto GBA for its Noninvasive Multi-Target Stool RNA Colorectal Cancer Screening Test

ST. LOUIS, April 12, 2023 / Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health,…


Oncology Tube Interview with Dr. David Lieberman, OHSU

Dr. David Lieberman discusses the Geneoscopy: Efficacy of Non-Invasive Colorectal Cancer Screening Test Evaluated in the CRC-PREVENT Phase 3 Trial……


Geneoscopy Joins White House for Cancer Moonshot Colorectal Cancer Forum

“As leaders, we have a responsibility to come together to impact cancer. Colorectal cancer is one of the most preventable and treatable cancers…


Health Tech: Erica Barnell On How Geneoscopy's Technology Can Make An Important Impact On Our Overall Wellness

"Embrace your flaws: Everyone has flaws. I feel that I have been successful because I am able to recognize these flaws,…


Geneoscopy Receives Accreditation from the College of American Pathologists (CAP) for its St. Louis Clinical Laboratory

Adds CAP Accreditation to Clinical Laboratory Improvement Amendments (CLIA) certification CAP ACCREDITATION ADDS TO GENEOSCOPY'S CLIA CERTIFICATION…


Colorectal Cancer: Screening Options and Potential Emerging Role for Pharmacists

Originally published July 1, 2022 Haytham Gareer, MD, PhD, MBA, FACS for Pharmacy Times   Nearly 63% of newly diagnosed patients have advanced…